AAX Biotech and ToxoTech partner to develop next-gen biotherapeutics for neurological disorders
Charlie Blackie-Kelly | November 7, 2025 | News story | Research and Development | AAX Biotech, Biotherapeutics, ToxoTech, neurological disorders
AAX Biotech, a biotech company specialising in next-generation antibody therapeutics, has entered a strategic partnership with ToxoTech, a biopharma company focused on neurological applications. The collaboration aims to develop new biotherapeutics for the treatment of neurological disorders.
“This project represents an exciting new application of Seqitope beyond its established use in antibody epitope mapping,” said Daniel X Johansson, CEO/CSO of AAX Biotech. “With our cutting-edge technologies to advance biologic drug discovery, we are pleased to collaborate with ToxoTech and leverage Seqitop to guide rational design and accelerate the development of precision-engineered biologics.”
Under the co-development agreement, the partners will combine AAX Biotech’s proprietary Seqitope platform – designed for high-throughput, high-resolution epitope mapping and stabilisation of single-chain variable fragments – with ToxoTech’s expertise in biologics drug design to create novel therapeutic candidates.
According to the companies, integrating the Seqitope platform into the discovery workflow is expected to optimise receptor recognition, enhancing both the potency and specificity of the resulting variants. The biotherapeutic candidates identified through this collaboration will be evaluated as potential treatments for neuromuscular and neurological disorders.
“At ToxoTech, we bring extensive experience in the drug design of biotherapeutics for neurology, and we see Seqitope as a valuable complement to our discovery pipeline. Working together with AAX Biotech allows us to accelerate the development of innovative therapies with the potential to transform treatment options across neurological and neuromuscular indications,” added Geoffrey Masuyer, CEO of ToxoTech.
Related Content
AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …
AAX Biotech announces collaboration for cardiovascular antibody therapy
Swedish biotech firm AAX Biotech has entered a new collaboration focused on the development of …
Autifony announces global license and collaboration agreement with Jazz Pharmaceuticals
Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz …
